SecBot SecBot
8-K ·Filed Nov 9, 2026

ADCT

ADC Therapeutics SA
NEUTRAL
Impact 4/10
Horizonweeks Processed7d 15h ago SEC0001628280-26-071899
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor ASH 2026 presentations (December 12-15) for updated LOTIS-7 and LOTIS-5 data, which could inform regulatory and compendia pathways. The financial restructuring removes near-term liquidity risk but dilution from the PIPE and warrants is a factor. Watch for FDA feedback on the LOTIS-5 sBLA and potential full approval.

DirectionNeutral
Confidencehigh
Horizonweeks

ZYNLONTA

◆ Mixed Named in this 8-K
Impact
Phase
Approved (accelerated approval); Phase 3 confirmatory (LOTIS-5) completed; Phase 1b combination (LOTIS-7) ongoing
Time to market
Already on the market (FDA accelerated approval April 2021). Path to full FDA approval is uncertain after LOTIS-5 safety issues. Japan decision timeline is not specified.
Next catalyst
None dated

What to watchWatch the 68th ASH Annual Meeting (December 5-8, 2026) where multiple ZYNLONTA abstracts will be presented, including updated LOTIS-7 combination data and potentially the full LOTIS-5 dataset. Also monitor the Japan marketing authorization decision by Tanabe Pharma (filed October 29, 2026) and any FDA guidance on the path to full approval. The stock trades near $1.51 with a 52-week range of $0.78-$4.98, reflecting deep uncertainty around the regulatory path.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.67
T+0 close · Nov 9, 2026 · via day close
Latest settled
−25.15%
T+5 · $1.25
Vs SPY
−23.46%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $1.67entry
  2. T+1 · 7d ago −9.58%α −9.21% · $1.51
  3. T+5 · 16h ago −25.15%α −23.46% · $1.25
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ADC Therapeutics reported Q3 2026 net product revenue of $21.0M, up 33% YoY from $15.8M, and a GAAP net loss of $0.16 per share, narrowing from a $0.30 loss a year ago. The company highlighted a strategic financial restructuring that included an $86.6M PIPE, debt reduction, and an extended cash runway into 2029, alongside upcoming ASH presentations for ZYNLONTA.

Key Financial Metrics

EPS (Adj.)
−$0.06
GAAP: $-0.16
Revenue
$21.0M
est $19.1M · +10.0% · +33.3% YoY

Key Facts

  • Q3 2026 net product revenue was $21.0M, up from $15.8M in Q3 2025, a 33% increase.
  • GAAP net loss per share was $0.16, compared to $0.30 in Q3 2025.
  • Adjusted net loss per share was $0.06, compared to $0.19 in Q3 2025.
  • Cash and cash equivalents were $189.2M as of September 30, 2026, with expected cash runway into 2029.
  • In October 2026, the company completed an $86.6M PIPE financing, issued 12.9M shares and 48M warrants, and reduced senior secured loan principal by $68.5M to $50M.
  • Multiple ZYNLONTA abstracts accepted for ASH 2026, including five oral presentations.
  • Japanese partner Tanabe Pharma submitted a marketing authorization application for ZYNLONTA in Japan.

Financial Impact

Q3 product revenue $21.0M (up 33% YoY); GAAP net loss $25.3M; cash $189.2M; PIPE $86.6M; debt reduced by $68.5M

revenuenet losscashdebt

Risk Factors

  • FDA raised serious concerns about LOTIS-5 trial results at a recent pre-sBLA submission meeting, creating regulatory uncertainty.
  • Dilution from 12.9M new shares and 48M warrants issued in the PIPE.
  • Company still operating at a net loss with $74.8M net loss for nine months.
  • Reliance on ZYNLONTA as sole marketed product; pipeline otherwise limited.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-071899
Document: adc-20261109.htm0001628280-26-071899
Document: 0001628280-26-071899-index-headers.html0001628280-26-071899
Document: 0001628280-26-071899-index.html0001628280-26-071899
Document: 0001628280-26-071899.txt0001628280-26-071899
8-K Data (Synthetic)0001628280-26-071899

US Market Status

Market Closed · Opens Wed (10h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026